Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Spanish Lung Cancer Group

ESMO 33

12 - 16 Sep 2008

Published: 3 Dec 2008

Views: 16576

Rating:

Save

Prof. Rafael Rosel

Benefits of customising erlotinib therapy for NSCLC.

Categories:
Lung & pleura

Related Videos

ESMO 2023: Highlights and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2023: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India

Lung Cancer ( Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India )

Innovative treatments for solid tumours – TTFields as a therapeutic modality

Dr Giuseppe Lombardi, Dr Helen Bulbeck, Prof Dean Fennell and Dr Tadeja Urbanic...

Innovative treatments for solid tumours – TTFields as a therapeutic modality ( Dr Giuseppe Lombardi, Dr Helen Bulbeck, Prof Dean Fennell and Dr Tadeja Urbanic-Purkart )

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during...

Prof Gerard Zalcman - Université de Paris, Paris, France

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients ( Prof Gerard Zalcman - Université de Paris, Paris, France )

The latest in NSCLC with common EGFR mutations

Dr Alfredo Addeo, Dr Antonio Passaro, Dr Alex Spira and Prof Amanda Tufman

The latest in NSCLC with common EGFR mutations ( Dr Alfredo Addeo, Dr Antonio Passaro, Dr Alex Spira and Prof Amanda Tufman )

ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC

Dr Joshua Sabari, Dr Enriqueta Felip and Dr Alex Spira

ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC ( Dr Joshua Sabari, Dr Enriqueta Felip and Dr Alex Spira )

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

OncoAlert Round Up for September 8-14, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 8-14, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Osimertinib plus chemotherapy shows superior results versus osimertinib alone...

Prof Pasi Janne - Dana Farber Cancer Institute, Boston, USA

Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated advanced lung cancer ( Prof Pasi Janne - Dana Farber Cancer Institute, Boston, USA )

More from ecancer